…
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company's helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Apyx Medical is a medical device company that develops and sells energy‑based systems and disposables for surgical and aesthetic soft‑tissue procedures. Long-term growth may be driven by rising demand for minimally invasive aesthetic treatments, broader clinical adoption of its technology, and recurring consumables sales, which could make the company attractive to investors seeking exposure to the medical aesthetics market.
The most important investment risks include regulatory scrutiny and product safety‑related liability, competitive pressure from larger device makers, and execution risk around commercialization and international expansion.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -10.84M | -23.31M | -21.28M | -22.91M | -14.82M |
| Minority interest | -0.11M | 0.10M | 0.14M | -0.09M | -0.03M |
| Net income | -11.21M | -23.46M | -18.71M | -23.28M | -15.20M |
| Selling general administrative | 36.12M | 43.12M | 48.87M | 48.15M | 43.73M |
| Selling and marketing expenses | - | - | 19.64M | - | - |
| Gross profit | 19.03M | 29.36M | 33.76M | 29.13M | 33.60M |
| Reconciled depreciation | 0.66M | 0.60M | 0.74M | 0.89M | 0.90M |
| Ebit | -6.45M | -17.40M | -18.80M | -23.56M | -14.45M |
| Ebitda | -5.79M | -16.80M | -18.11M | -22.90M | -14.81M |
| Depreciation and amortization | 0.66M | 0.60M | 0.69M | 0.67M | -0.36M |
| Non operating income net other | - | - | - | 0.65M | -0.37M |
| Operating income | -6.45M | -18.84M | -17.26M | -23.56M | -14.45M |
| Other operating expenses | 59.29M | 66.95M | 69.61M | 68.07M | 62.97M |
| Interest expense | 5.59M | 5.91M | 2.48M | 0.01M | 0.01M |
| Tax provision | 0.27M | 0.25M | -2.37M | 0.37M | 0.38M |
| Interest income | 1.11M | 1.61M | 0.54M | 0.16M | 0.01M |
| Net interest income | -4.48M | -4.30M | -0.82M | 0.14M | 0.00M |
| Income tax expense | 0.27M | 0.25M | -2.43M | 0.37M | 0.38M |
| Total revenue | 52.84M | 48.10M | 52.35M | 44.51M | 48.52M |
| Total operating expenses | 25.48M | 48.20M | 51.02M | 52.69M | 48.05M |
| Cost of revenue | 33.81M | 18.74M | 18.59M | 15.38M | 14.92M |
| Total other income expense net | -4.39M | -4.46M | -4.02M | 0.65M | -0.37M |
| Net income from continuing ops | -11.11M | -23.56M | -15.29M | -23.28M | -15.20M |
| Net income applicable to common shares | - | - | - | -23.18M | -15.17M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 66.84M | 64.84M | 79.24M | 51.77M | 68.72M |
| Other current assets | 1.35M | 1.66M | 2.73M | 2.74M | 1.93M |
| Total liab | 52.01M | 50.51M | 52.32M | 13.98M | 14.71M |
| Total stockholder equity | 14.54M | 14.21M | 26.70M | 37.58M | 53.70M |
| Other current liab | 8.21M | 7.06M | 9.17M | 8.07M | 1.86M |
| Common stock | 0.04M | 0.04M | 0.04M | 0.04M | 0.03M |
| Capital stock | 0.04M | 0.04M | 0.04M | 0.04M | 0.03M |
| Retained earnings | -89.12M | -77.91M | -54.45M | -35.73M | -12.55M |
| Other liab | - | - | - | 1.59M | 1.49M |
| Other assets | - | - | - | 1.22M | 1.11M |
| Cash | 31.74M | 31.74M | 43.65M | 10.19M | 30.87M |
| Total current liabilities | 11.70M | 10.72M | 12.74M | 11.85M | 13.21M |
| Current deferred revenue | - | 0.69M | 0.49M | 0.85M | 8.42M |
| Net debt | 7.60M | 7.02M | -5.15M | -9.40M | -30.57M |
| Short term debt | 0.43M | 0.35M | 0.37M | 0.25M | 0.29M |
| Short long term debt total | 39.34M | 38.76M | 38.50M | 0.80M | 0.30M |
| Other stockholder equity | 103.62M | 92.08M | 81.11M | 73.28M | 66.22M |
| Property plant equipment | - | - | - | 6.76M | 6.58M |
| Total current assets | 58.47M | 56.44M | 70.36M | 42.97M | 60.74M |
| Net tangible assets | - | - | - | 37.58M | 53.70M |
| Net receivables | 16.78M | 15.48M | 14.05M | 18.25M | 21.16M |
| Long term debt | 34.85M | 33.89M | 33.19M | - | - |
| Inventory | 8.60M | 7.56M | 9.92M | 11.80M | 6.78M |
| Accounts payable | 3.06M | 2.62M | 2.71M | 2.67M | 2.63M |
| Noncontrolling interest in consolidated entity | - | - | - | 0.21M | 0.30M |
| Accumulated other comprehensive income | - | - | 0.00M | - | - |
| Common stock total equity | - | - | - | 0.04M | 0.03M |
| Retained earnings total equity | - | - | - | -35.73M | -12.55M |
| Non currrent assets other | 1.75M | 1.66M | 1.73M | 1.22M | 1.11M |
| Non current assets total | 8.37M | 8.40M | 8.88M | 8.80M | 7.98M |
| Capital lease obligations | 4.49M | 4.87M | 5.32M | 0.80M | 0.30M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.72M | 6.68M | -1.01M | -0.72M |
| Change to liabilities | - | - | - | -1.14M | 4.55M |
| Total cashflows from investing activities | -1.11M | -0.72M | 6.73M | -1.01M | -0.72M |
| Net borrowings | -0.02M | -0.02M | 35.04M | -0.15M | -0.24M |
| Total cash from financing activities | 9.58M | 6.75M | 32.17M | 0.22M | 0.02M |
| Change to operating activities | - | - | - | -1.73M | 4.75M |
| Net income | -11.11M | -23.56M | -18.85M | -23.28M | -15.20M |
| Change in cash | -0.00M | -11.91M | 33.46M | -20.68M | -11.04M |
| Begin period cash flow | 31.74M | 43.65M | 10.19M | 30.87M | 41.91M |
| End period cash flow | 31.74M | 31.74M | 43.65M | 10.19M | 30.87M |
| Total cash from operating activities | -8.00M | -18.05M | -5.25M | -20.28M | -10.45M |
| Issuance of capital stock | 9.30M | 7.00M | 0.00M | - | - |
| Depreciation | 0.66M | 0.60M | 0.69M | 0.89M | 0.90M |
| Other cashflows from investing activities | - | - | -0.15M | - | - |
| Change to inventory | -1.07M | 2.26M | 1.46M | -5.57M | -2.86M |
| Change to account receivables | -1.32M | -2.04M | 3.97M | 1.92M | -4.90M |
| Sale purchase of stock | - | - | - | - | 0.20M |
| Other cashflows from financing activities | 0.06M | -0.23M | -5.59M | 0.36M | 0.26M |
| Change to netincome | - | - | - | 7.09M | 5.58M |
| Capital expenditures | 1.11M | 0.72M | 0.53M | 1.01M | 0.72M |
| Change receivables | - | - | - | 1.92M | -4.90M |
| Cash flows other operating | - | - | - | -0.19M | 1.48M |
| Cash and cash equivalents changes | - | - | - | -21.07M | -11.15M |
| Change in working capital | -1.59M | -1.25M | 5.54M | -5.22M | -1.84M |
| Stock based compensation | 2.00M | 4.01M | 5.11M | 6.70M | 5.09M |
| Other non cash items | 2.04M | 2.15M | 2.25M | 0.63M | 0.60M |
| Free cash flow | -9.12M | -18.77M | -5.78M | -21.29M | -11.17M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| APYX Apyx Medical Inc |
0.07 2.39% |
3.00 | - | 72.46 | 3.09 | 11.22 | 3.23 | -5.33 |
| ABT Abbott Laboratories |
-0.36 0.33% |
109.56 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.14 0.14% |
101.66 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-0.84 0.26% |
325.03 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-2.15 4.12% |
49.85 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company's helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
5115 Ulmerton Road, Clearwater, FL, United States, 33760-4004
727 384 2323
205
| Name | Title | Year Born |
|---|---|---|
| Mr. Charles D. Goodwin II | Pres, CEO & Director | 1966 |
| Ms. Tara H. Semb | CFO, Treasurer & Sec. | 1970 |
| Mr. Moshe Citronowicz | Sr. VP | 1953 |
| Mr. Todd Hornsby | Exec. VP | 1976 |
| Mr. Charles D. Goodwin II | President, CEO & Director | 1967 |
| Mr. Matthew C. Hill CPA | CFO, Treasurer & Secretary | 1969 |
| Mr. Moshe Citronowicz | Senior Vice President | 1953 |
| Mr. Todd Hornsby | Executive Vice President | 1977 |
| Mr. Shawn D. Roman | Chief Operating Officer | 1972 |
| Ms. Dolores Catania | Chief of Confidence | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.